Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease (EPIC-CAD)

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Gi-Byoung Nam
Updated on 9 July 2022
computed tomography angiography
artery disease
atrial fibrillation
angina pectoris
percutaneous coronary intervention
coronary artery stenosis
stable angina
antiplatelet agents
bypass graft
acute coronary syndrome
coronary artery bypass graft
vascular disease
coronary artery bypass
bypass surgery
arterial disease


This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months for acute coronary syndrome and ≥ 6 months after stable CAD]) and high-risk atrial fibrillation (CHA2DS2-VASc score ≥2).

Condition Atrial Fibrillation, Coronary Artery Disease, Stable Angina, Stable Chronic Angina
Treatment Edoxaban, Single Antiplatelet Agents
Clinical Study IdentifierNCT03718559
SponsorGi-Byoung Nam
Last Modified on9 July 2022


Yes No Not Sure

Inclusion Criteria

A subject was ≥ 19 years of age
Patients with nonvalvular atrial fibrillation with high embolic risk (CHA2DS2-VASc score ≥2)
Patients with Stable coronary artery disease
Coronary artery angiography or Coronary Computed Tomography Angiography confirmed coronary artery disease (≥50 % stenosis of a major coronary artery) on medical treatment. In case there is clinically significant moderate or more stenosis however the percentage of stenosis on CAG or CCTA is not shown, it will be at the investigator's discretion
Revascularized coronary artery disease (either Percutaneous Coronary Intervention or coronary bypass surgery) whom the last revascularization should be performed ≥12 months before study enrollment for the acute coronary syndrome and ≥6 months for stable angina pectoris

Exclusion Criteria

Patients with thrombocytopenia
High risk of bleeding which prohibits the anticoagulant use. (baseline comorbidities, hyper or hypercoagulable state, increased prothrombin time or activated partial thromboplastin time)
Prior history of intracranial haemorrhage or haemorrhage on Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) imaging test
Mechanical prosthetic valve or moderate to severe mitral stenosis
The risk of bleeding increased due to the following reasons; i. history of gastrointestinal ulcers within 1 month ii. Malignant tumor with high risk of bleeding iii. Brain or spinal cord injury within 1 month iv. History of intracranial or intracerebral hemorrhage within 12 months v. Esophageal varices vi. Arteriovenous malformation vii. Vascular aneurysms viii. Spinal cord vascular abnormalities or intracerebral vascular abnormalities ix. Active bleeding x. Hemoglobin level <7.0 g/dL or platelet count ≤ 50,000 / mm3 xi. History of major surgery within 1 month
Uncontrolled severe hypertension
Hemodynamically Unstable or pulmonary embolism requiring thrombolysis or pulmonary embolectomy
History of hypersensitivity to Edoxaban or clopidogrel
Genetic problem with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
Planned Percutaneous Coronary Intervention or coronary bypass surgery was planned within 1 year after randomization
Liver cirrhosis or liver dysfunction (AST or ALT > x3 of normal range or coagulation abnormality)
Estimated CrCl by Cockcroft-Gault equation<15 mL/min
Life expectancy less than 12 months
The subject was unable to provide written informed consent or participate in long-term follow-up
Pregnant and/or lactating women
Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note